Brainstorm announces expansion of nurown® ip portfolio with grant and allowance of multiple patents and applications in major markets

New york, june 15, 2021 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the grant and/or allowance of a series of patents and patent applications. these patents and patent applications, which were granted/allowed in 2020 and 2021, are expected to provide broad protection for brainstorm's proprietary nurown® (msc-ntf cells) technology in territories including the u.s., e.u.
BCLI Ratings Summary
BCLI Quant Ranking